Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15461703 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1WNT3A | |
| SCHEMBL13377947 | 0.79 | ALDH1A1 (0.43) | KDM4EALDH1A1RAB9ALMNA | |
| SCHEMBL898825 | 0.74 | POLB (0.47) | KDM4EALDH1A1LMNA | |
| SCHEMBL874433 | 0.74 | L3MBTL1 (0.43) | KDM4EALDH1A1RAB9ALMNA | |
| SCHEMBL9947197 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL24070271 | 0.70 | KDM4E (0.41) | KDM4EALDH1A1RAB9AFAAHAPEX1 | |
| SCHEMBL2339894 | 0.69 | HRH1 (0.39) | KDM4EALDH1A1LMNA | |
| SCHEMBL2344594 | 0.69 | POLB (0.46) | KDM4EALDH1A1 | |
| SCHEMBL2339880 | 0.69 | L3MBTL1 (0.42) | KDM4EALDH1A1RAB9ALMNA | |
| SCHEMBL3829493 | 0.68 | KMT2A (0.63) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351274-B2 | Methods of using optical agents | MEDIBEACON INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC. | 2022-04-28 | — | — | US | disclosed |
| US-11185597-B2 | Process for using optical agents | MEDIBEACON, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-10695445-B2 | Methods of using optical agents | MEDIBEACON INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190192695-A1 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190192696-A1 | METHODS OF USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190022256-A1 | METHODS OF USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-01-24 | — | — | US | disclosed |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | Medibeacon, LLC | 2017-10-19 | — | — | US | disclosed |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC (US) | 2016-09-29 | — | — | US | disclosed |
| US-8778309-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778309-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140039191-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | Medibeacon, LLC (US) | 2014-02-06 | — | — | US | disclosed |
| EP-1836175-B1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2135863-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080312539-A1 | Methods of Using Optical Agents | MEDIBEACON, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312539-A1 | Methods of Using Optical Agents | MEDIBEACON, INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1854790-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, XDH, CYP4F12 | KDM4E 2713/4885ALDH1A1 546/4885RAB9A 4234/4885 |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | GLS, CYP4F12, XDH | KDM4E 3146/4885ALDH1A1 393/4885RAB9A 4156/4885 |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | KDM4E 3146/4885ALDH1A1 393/4885RAB9A 4156/4885 |
| US-10695445-B2 | Methods of using optical agents | REN, ATP6V1B1, VHL | KDM4E 3068/4885ALDH1A1 2024/4885RAB9A 1018/4885 |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | KDM4E 3146/4885ALDH1A1 393/4885RAB9A 4156/4885 |
| US-20190022256-A1 | METHODS OF USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | KDM4E 3068/4885ALDH1A1 2024/4885RAB9A 1018/4885 |
| US-20190192695-A1 | PROCESS FOR USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | KDM4E 2757/4885ALDH1A1 1866/4885RAB9A 889/4885 |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | KDM4E 3146/4885ALDH1A1 393/4885RAB9A 4156/4885 |
| US-20140039191-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | KDM4E 3146/4885ALDH1A1 393/4885RAB9A 4156/4885 |
| US-11185597-B2 | Process for using optical agents | REN, ATP6V1B1, VHL | KDM4E 2757/4885ALDH1A1 1866/4885RAB9A 889/4885 |
| US-11351274-B2 | Methods of using optical agents | REN, ATP6V1B1, VHL | KDM4E 3068/4885ALDH1A1 2024/4885RAB9A 1018/4885 |
| US-20190192696-A1 | METHODS OF USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | KDM4E 3068/4885ALDH1A1 2024/4885RAB9A 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.